AD News Today: Stay Updated with the Latest Array Digital Infrastructure, Inc. News in Real Time
Find AD news now at Meyka AI. Stay informed with the latest{" "} Array Digital Infrastructure, Inc. stocks updates, including price news, market analysis, and expert insights.
SK Hynix Seals Multi-Year AI Deal With Nvidia, June 08
SK Hynix signs multi-year partnership with Nvidia to develop advanced memory for AI data centers. Deal secures supply as memory demand surges.
Cash Withdrawal Rules in Germany: What You Need to Know, June 08
German ATM withdrawal rules: 30-second card retrieval, free withdrawals vary by bank. Learn costs, limits, and avoid losing your card.
French Telecoms Agree €20.35B SFR Breakup Deal, June 08
Orange, Bouygues, and Free-Iliad to acquire SFR from Altice France for €20.35 billion in major French telecoms deal pending regulatory approval.
Delta Air Lines Returns to Hong Kong With Daily LA Nonstop, June 09
Delta resumes Hong Kong-Los Angeles nonstop flights with Airbus A350-900, expanding Asia-Pacific network amid industry fuel cost pressures.
Solana USD Drops 7.15% Daily: SOLUSD Tests $64.91 Support
SOLUSD drops 7.15% daily to $67.22. RSI at 20 signals oversold conditions. Technical analysis shows strong downtrend with ADX at 26.41.
TVS Motor Launches Premium Paddock Retail Network, June 08
TVS Motor launches TVS Paddock premium retail network in Q2 FY27 for Apache, Norton motorcycles, and future EVs with customization options.
ILA 2026 Draws 750 Exhibitors to Berlin as Region Booms, June 08
ILA 2026 aerospace show opens June 10 with 750 exhibitors from 37 countries. Berlin Airport handled 26.1M passengers in 2025, up 2.3%.
BP Shares Fall 12% to £5.46 as Oil Peace Deal Weighs, June 08
BP shares fall 12% to £5.46 on Iran peace deal expectations. JPMorgan holds 600p target; analyst consensus at 635p. CEO change supports oil focus.
Eli Lilly Stock (LLY) Jumps 4% to $1,131.42 USD as Retatrutide Cuts Sleep Apnea by 60% in Phase 3 Trial
Eli Lilly stock gained approximately 4 percent and climbed to $1,131.42 USD after the company announced promising Phase 3 clinical trial results for Retatrutide. The experimental drug demonstrated a remarkable ability to reduce obstructive sleep apnea severity by nearly 60 percent, generating excitement among investors and healthcare professionals. The announcement strengthened confidence in Eli Lilly’s…